<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201106116689N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-11-05</date_registration>
      <primary_sponsor>Vice Chancellor for Research, Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Treatment of endometrioma in infertile     women</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of ovarian response to ovulation induction after laparoscopic cystectomy or medical management among infertile women with endometrioma undergoing assisted reproductive technology</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-01-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/7099</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: All volenteers with inclusion criteria are asked to participate in the current study if agreed, a informed consent form is signed. she is randomly assigned to one of two groups based in Bertoli distribution. If she has an objection, we will switch her to another group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Infertility. Condition 2: Endometriomas.</hc_freetext>
      <i_freetext>Intervention 1: First group receives 3 consecutive single IM doses of Dipherelin 3.75mg (Beaufouipfen, France) in 3 consecutive months.Ten days after the third IM dose of Dipherelin ovarian stimulation is conducted by using Gonal F (Serono, Switzerland, 300-450IU daily), for one week. Then Gonal F is replaced by HMG (Ferring, Germany, 300-450IU daily) until the observation of 18mm follicles in trans vaginal ultrasound. For visualizing follicular development, trans vaginal ultrasound (Sonoline G20; Siemens Medical Solutions, California, USA) is performed every 4 days. After the observation of at least two 18mm follicles, HCG (Ferring Co, Germany, 10000IU, IM) is injected and after 36 hours oocyte retrieve is performed under general anesthesia. Three days after fertilization technique performed through intra cytoplasmic sperm injection (ICSI), trans cervical embryo transfer will be carried out. Detection of pregnancy is through serum BhCG analysis, 3 days after embryonic transfer and the clinical pregnancy is detected by the aid of trans vaginal ultrasound, two weeks later when the pregnancy sac is detected. Main outcome is the number of oocytes retrieved. The number of oocytes retrieved, dominant follicles, embryos; quality of embryos;the rate of fertilization, laboratory and clinical pregnancy are compared between two groups. Intervention 2: Second group receives 3 consecutive single IM doses of Dipherelin 3.75mg (Beaufouipfen, France) in 3 consecutive months after laparoscopic ovarian cystectomy. Ten days after the third IM dose of Dipherelin ovarian stimulation is conducted by using Gonal F (Serono, Switzerland, 300-450IU daily), for one week. Then Gonal F is replaced by HMG (Ferring, Germany, 300-450IU daily) until the observation of 18mm follicles in trans vaginal ultrasound. For visualizing follicular development, trans vaginal ultrasound (Sonoline G20, Siemens Medical Solutions, California, USA) is performed every 4 days. After observing at least two 18mm follicles, HCG (Ferring Co, Germany, 10000IU, IM) is injected and after 36 hours oocyte retrieve is performed under general anesthesia. Three days after fertilization technique performed through intra cytoplasmic sperm injection (ICSI), trans cervical embryo transfer is carried out. Detection of pregnancy is  through serum BhCG analysis, 3 days after embryonic transfer and the clinical pregnancy is detected by the aid of trans vaginal ultrasound, two weeks later when the pregnancy sac is detected. Main outcome is the number of oocytes retrieved. The number of oocytes retrieved, dominant follicles, embryos; quality of embryos;the rate of fertilization, laboratory and clinical pregnancy are compared between two groups.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Sedighe Hoseinimosa</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Infertility Department, Shariati Hospital, North Karegar Street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8800 8810</telephone>
        <email>hoseinimosa@razi.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences, Shariati Hospital, Department of Infertility</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Leili Safdarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Infertility Department, Shariati Hospital, North Karegar Street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8800 8810</telephone>
        <email>safdarian@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Infertile women with endometrioma requiring assisted reproductive technology&#13;
 Exclusion criteria: Age over 40 years; Endometrioma smaller than 2 cm or larger than 6 cm; Male infertility TESE (Testicular Sperm Extraction) or PESA (Percutaneous Epididimal Sperm Aspiration)</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97</hc_code>
      <hc_code>N80.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>ناباروري زنانه</hc_keyword>
      <hc_keyword>اندومتريوزيزدرتخمدان</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First group receives 3 consecutive single IM doses of Dipherelin 3.75mg (Beaufouipfen, France) in 3 consecutive months.Ten days after the third IM dose of Dipherelin ovarian stimulation is conducted by using Gonal F (Serono, Switzerland, 300-450IU daily), for one week. Then Gonal F is replaced by HMG (Ferring, Germany, 300-450IU daily) until the observation of 18mm follicles in trans vaginal ultrasound. For visualizing follicular development, trans vaginal ultrasound (Sonoline G20; Siemens Medical Solutions, California, USA) is performed every 4 days. After the observation of at least two 18mm follicles, HCG (Ferring Co, Germany, 10000IU, IM) is injected and after 36 hours oocyte retrieve is performed under general anesthesia. Three days after fertilization technique performed through intra cytoplasmic sperm injection (ICSI), trans cervical embryo transfer will be carried out. Detection of pregnancy is through serum BhCG analysis, 3 days after embryonic transfer and the clinical pregnancy is detected by the aid of trans vaginal ultrasound, two weeks later when the pregnancy sac is detected. Main outcome is the number of oocytes retrieved. The number of oocytes retrieved, dominant follicles, embryos; quality of embryos;the rate of fertilization, laboratory and clinical pregnancy are compared between two groups.</i_keyword>
      <i_keyword>Second group receives 3 consecutive single IM doses of Dipherelin 3.75mg (Beaufouipfen, France) in 3 consecutive months after laparoscopic ovarian cystectomy. Ten days after the third IM dose of Dipherelin ovarian stimulation is conducted by using Gonal F (Serono, Switzerland, 300-450IU daily), for one week. Then Gonal F is replaced by HMG (Ferring, Germany, 300-450IU daily) until the observation of 18mm follicles in trans vaginal ultrasound. For visualizing follicular development, trans vaginal ultrasound (Sonoline G20, Siemens Medical Solutions, California, USA) is performed every 4 days. After observing at least two 18mm follicles, HCG (Ferring Co, Germany, 10000IU, IM) is injected and after 36 hours oocyte retrieve is performed under general anesthesia. Three days after fertilization technique performed through intra cytoplasmic sperm injection (ICSI), trans cervical embryo transfer is carried out. Detection of pregnancy is  through serum BhCG analysis, 3 days after embryonic transfer and the clinical pregnancy is detected by the aid of trans vaginal ultrasound, two weeks later when the pregnancy sac is detected. Main outcome is the number of oocytes retrieved. The number of oocytes retrieved, dominant follicles, embryos; quality of embryos;the rate of fertilization, laboratory and clinical pregnancy are compared between two groups.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The number of retrieved oocytes. Timepoint: 84 days after the first Dipherelin injection. Method of measurement: Invert  Microscope, Diaphot 300,  Nikon, Japan.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The number of dominant follicles. Timepoint: 82 days after the first Dipherelin injection. Method of measurement: nGS=  number of observed gestatinal sac in trans vaginal sonography, nET= number of embryonal transfer, clinical pregnancy rate(%)= nGS/ nET x100.</sec_outcome>
      <sec_outcome>Fertilization rate. Timepoint: 87 days after the first Dipherelin injection. Method of measurement: nE= number of total embryos, nI= number of injected oocytes, fertilization rate(%)= nE/ nI x 100.</sec_outcome>
      <sec_outcome>The number and quality of embryos. Timepoint: 87 days after the first Dipherelin injection. Method of measurement: Invert  Microscope, Diaphot 300, Nikon, Japan.</sec_outcome>
      <sec_outcome>Chemical pregnancy. Timepoint: 101 days after the first Dipherelin injection. Method of measurement: βhCG test.</sec_outcome>
      <sec_outcome>Clinical pregnancy rate. Timepoint: 115 days after the first Dipherelin injection. Method of measurement: nGS=  number of observed gestatinal sac in trans vaginal sonography, nET= number of embryonal transfer, clinical pregnancy rate(%)= nGS/ nET x100.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for Research, Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-01-02</approval_date>
        <contact_name>Ethic Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Ethic Committee, Tehran University of Medical Sciences, Poorsina Street, Tehran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
